Asahi Intecc Co Ltd develops, manufactures, and sells medical devices... Show more
On August 14, 2025, the Stochastic Oscillator for AHICF moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 8 instances where the indicator left the oversold zone. In of the 8 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AHICF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.669) is normal, around the industry mean (10.930). P/E Ratio (55.824) is within average values for comparable stocks, (62.278). AHICF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.881). Dividend Yield (0.009) settles around the average of (0.016) among similar stocks. P/S Ratio (5.924) is also within normal values, averaging (39.773).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHICF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
ILF | 26.12 | 0.27 | +1.04% |
iShares Latin America 40 ETF | |||
EMEQ | 31.27 | 0.06 | +0.20% |
Macquarie Focused Emerging Mrkts Eq ETF | |||
PSMJ | 30.97 | 0.03 | +0.11% |
Pacer Swan SOS Moderate (July) ETF | |||
FBUF | 28.96 | -0.04 | -0.14% |
Fidelity Dynamic Buffered Equity ETF | |||
VIXY | 37.97 | -0.17 | -0.45% |
ProShares VIX Short-Term Futures |
A.I.dvisor indicates that over the last year, AHICF has been loosely correlated with AIMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AHICF jumps, then AIMD could also see price increases.
Ticker / NAME | Correlation To AHICF | 1D Price Change % | ||
---|---|---|---|---|
AHICF | 100% | N/A | ||
AIMD - AHICF | 46% Loosely correlated | -9.42% | ||
AMBFF - AHICF | 32% Poorly correlated | N/A | ||
TDVXF - AHICF | 20% Poorly correlated | N/A | ||
BVS - AHICF | 10% Poorly correlated | +0.41% | ||
NMTC - AHICF | 7% Poorly correlated | -1.23% | ||
More |
Ticker / NAME | Correlation To AHICF | 1D Price Change % |
---|---|---|
AHICF | 100% | N/A |
Pharmaceuticals category (394 stocks) | 3% Poorly correlated | -1.04% |
Pharmaceuticals: Other category (105 stocks) | 1% Poorly correlated | -0.56% |